LRP as Applicant or as Defendant: The Shift Under Statutory Regulation

1. Key takeaways

Under the current arrangement the LRP occupies a double position: it is the applicant that files the listing and, at the same time, the responsible person that carries post-market obligations. Once the regime is placed on a statutory footing, that role shifts in 2 decisive ways. The first is a shift from voluntary assumption to statutory assumption, so that obligations arise from legislation rather than from a contract of appointment. The second is a shift from being a party to a particular device listing to being the responsible subject for all devices supplied in Hong Kong, China, with coverage extending to Class I and Class A as the legislation expands.

Neither shift can be managed after the event. A contract that allocates duties on the assumption that the LRP is a voluntary service provider will be describing an entity that no longer exists in that form. An adjustment mechanism therefore has to be written into the agreement now, while the commercial relationship is calm and the bargaining positions are still balanced.

The direction of travel is documented rather than speculative. The government has stated in writing that, after legislation, all medical devices supplied in Hong Kong, China must be registered unless exempt, and has stated that it will introduce legislative proposals during the year. What remains open is timing and final scope, not the principle.

2. Legal basis

The clearest statement of the post-legislation position is in the government reply to a Legislative Council question, press release P2025070900329 of 9 July 2025, whose final paragraph records that all medical devices supplied in Hong Kong, China will have to be registered unless exempt once legislation is in place. The background brief prepared by the Legislative Council Secretariat for the Panel on Health Services meeting of 10 April 2026, document CB3-261-4 of 31 March 2026, addresses the same subject at paragraphs 15 and 16. A further press release, P2026020300240 of 3 February 2026, issued in connection with the Department of Health regulatory symposium on medical devices, records that the government will submit legislative proposals to regulate medical devices this year. The current obligations of an LRP remain in COP-01, and the current reporting obligations in GN-03, both in versions verified to 29 October 2026.

The significance of the legal basis is that the existing duties and the future duties rest on different foundations. Today an LRP is bound because it accepted an appointment and because the listing system requires it. Under legislation it will be bound because the law says so. The same words in a contract therefore carry different weight before and after commencement, and a clause drafted today without that distinction will be read against the LRP in a way the manufacturer did not intend.

3. Expert insights

The registration-unless-exempt formula changes the basis of the obligation. A voluntary listing presupposes a voluntary application. Once a statutory duty exists, supplying an unregistered device becomes unlawful, and the LRP, as the local subject, is first in the enforcement line. This change cannot be contracted away: a statutory duty is not transferable by private agreement, and an indemnity from an overseas manufacturer does not answer a regulator.

An expanded scope changes the workload structure, not merely the volume. The current MDACS covers Class II and above; Class I general medical devices and Class A IVDMD fall outside it. If the statutory regime brings them fully within scope, the number of SKUs an LRP manages may multiply, a practical estimate rather than a published projection. Volume growth of that kind changes staffing, record systems and fee structures at once, because each additional SKU carries the same four post-market obligations as an existing one.

Integration into the CMPR will change the counterpart interface. The government has said it will integrate the Department of Health service units currently responsible for western medicines, Chinese medicines and medical devices into the Centre for Medical Products Regulation, to be established by the end of 2026. For an LRP this means the counterpart, the form system and the numbering conventions may all change together. A file structure built around the current unit will need mapping to a new one, and the transition period is exactly when documentation gaps become visible.

A contract can solve internal recourse but not external liability. Manufacturer and LRP may agree on how responsibility and compensation are shared, and such clauses are worth having. What they cannot do is redirect the regulator: the party pursued remains the LRP. That asymmetry is the reason the selection of an LRP should weigh capability above price, and the reason a low fee is a poor indicator of value in this role.

The coverage question has a commercial edge. Class I devices and Class A IVDs are typically the high-volume, low-margin part of a portfolio. If they enter scope, the cost of maintaining them in compliance may exceed their margin unless the process is standardised. Manufacturers should model that segment separately rather than averaging it into the portfolio.

4. Practical recommendations

• Insert a regulatory change clause into the contract. Agree that, once legislation commences, the parties will renegotiate the allocation of obligations, the fee and the transfer of documents, with a defined trigger date and a defined negotiation period.
• Expand the compliance team ahead of the change. Estimate headcount against the possible SKU population after statutory coverage, and build the record and vigilance systems before the volume arrives rather than after.
• Build an evidence system that can be migrated. Organise technical documentation, quality system certificates and post-market records in an internationally conventional structure, so that a change of counterpart, form or numbering system does not require rebuilding the file.
• Track the legislative process and reserve a response window. Use the Legislative Council Panel on Health Services papers and Department of Health press releases as the monitoring sources, and set a quarterly review with a named owner.
• Separate internal recourse from regulatory exposure in the contract. Record explicitly that indemnities operate between the parties only and do not alter the LRP position before the authority.

5. Verification checklist

• □ LRP appointment contract contains a regulatory change adjustment clause with a defined trigger.
• □ SKU population and headcount estimated against the possible post-legislation coverage, including Class I and Class A.
• □ Record and vigilance systems built in a form that can be migrated to a new authority interface.
• □ Internal recourse mechanism agreed and expressly separated from external liability.
• □ Quarterly review of legislative progress established with a named owner.
• □ Expected change of counterpart interface after CMPR establishment documented and monitored.
• □ Current obligations under COP-01 and GN-03 confirmed against the versions verified to 29 October 2026.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team coordinates local responsible persons, import and wholesale dealer licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com